GlassScriptPhysician profile
Michael Kornberg
NPI 1174786834
$7,283.10
in general payments reported to CMS, 2019-2025
19 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $515 · 2021: $202 · 2022: $1,100 · 2023: $1,287 · 2024: $1,335 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.79 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,620.13 | 2019-2025 | Rexulti |
| Abbvie INC. | $824.31 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $805.46 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $793.99 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $772.43 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $622.57 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $512.06 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $362.09 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $265.32 | 2019-2025 | Fanapt |
| Allergan, INC. | $183.85 | 2019-2020 | |
| Shire North American Group INC | $178.21 | 2019 | |
| Corium, LLC | $83.99 | 2023 | Azstarys |
| Tris Pharma INC | $79.91 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $52.19 | 2019 | |
| Neurocrine Biosciences, INC. | $49.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.63 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $22.44 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kornberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.